MEDIFAST INC (MED) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:MED - US58470H1014 - Common Stock
11.42 USD
+0.39 (+3.54%)
11.42 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to MED. MED was compared to 36 industry peers in the Personal Care Products industry. MED has a great financial health rating, but its profitability evaluates not so good. MED does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
MED had negative earnings in the past year.
MED had a positive operating cash flow in the past year.
In the past 5 years MED has always been profitable.
In the past 5 years MED always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of 0.09%, MED perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
MED has a Return On Equity of 0.12%. This is comparable to the rest of the industry: MED outperforms 58.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.09% | ||
| ROE | 0.12% | ||
| ROIC | N/A |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MED (0.06%) is comparable to the rest of the industry.
MED's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of MED has declined.
With a decent Gross Margin value of 72.44%, MED is doing good in the industry, outperforming 72.22% of the companies in the same industry.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.06% | ||
| GM | 72.44% |
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
2. Health
2.1 Basic Checks
MED does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MED has more shares outstanding
Compared to 5 years ago, MED has less shares outstanding
There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.58 indicates that MED is not in any danger for bankruptcy at the moment.
MED has a better Altman-Z score (4.58) than 83.33% of its industry peers.
MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.58 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
MED has a Current Ratio of 4.45. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 4.45, MED belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
A Quick Ratio of 3.95 indicates that MED has no problem at all paying its short term obligations.
The Quick ratio of MED (3.95) is better than 86.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.45 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
The earnings per share for MED have decreased strongly by -100.00% in the last year.
The earnings per share for MED have been decreasing by -20.59% on average. This is quite bad
Looking at the last year, MED shows a very negative growth in Revenue. The Revenue has decreased by -36.29% in the last year.
Measured over the past years, MED shows a decrease in Revenue. The Revenue has been decreasing by -3.33% on average per year.
EPS 1Y (TTM)-100%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-160%
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-36.21%
3.2 Future
Based on estimates for the next years, MED will show a very negative growth in Earnings Per Share. The EPS will decrease by -43.69% on average per year.
The Revenue is expected to decrease by -23.25% on average over the next years. This is quite bad
EPS Next Y-78.11%
EPS Next 2Y-43.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
MED is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 194.28 | ||
| EV/EBITDA | -15.22 |
4.3 Compensation for Growth
A cheap valuation may be justified as MED's earnings are expected to decrease with -43.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.69%
EPS Next 3YN/A
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 9.97%, which is a nice return.
MED's Dividend Yield is rather good when compared to the industry average which is at 2.04. MED pays more dividend than 97.22% of the companies in the same industry.
MED's Dividend Yield is rather good when compared to the S&P500 average which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
5.2 History
The dividend of MED decreases each year by -53.42%.
MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-53.42%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
78.63% of the earnings are spent on dividend by MED. This is not a sustainable payout ratio.
The Dividend Rate of MED has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.
DP78.63%
EPS Next 2Y-43.69%
EPS Next 3YN/A
11.42
+0.39 (+3.54%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners84.91%
Inst Owner Change-0.05%
Ins Owners3.3%
Ins Owner Change0%
Market Cap125.51M
Revenue(TTM)429.69M
Net Income(TTM)248.00K
Analysts46.67
Price Target15.3 (33.98%)
Short Float %18.76%
Short Ratio8.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
Yearly Dividend0.07
Dividend Growth(5Y)-53.42%
DP78.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.85%
Min EPS beat(2)46.69%
Max EPS beat(2)199.01%
EPS beat(4)4
Avg EPS beat(4)116.81%
Min EPS beat(4)46.69%
Max EPS beat(4)199.01%
EPS beat(8)6
Avg EPS beat(8)95.8%
EPS beat(12)10
Avg EPS beat(12)87.61%
EPS beat(16)13
Avg EPS beat(16)70.85%
Revenue beat(2)2
Avg Revenue beat(2)7.01%
Min Revenue beat(2)5.26%
Max Revenue beat(2)8.75%
Revenue beat(4)4
Avg Revenue beat(4)5.3%
Min Revenue beat(4)3.13%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)3.21%
Revenue beat(12)11
Avg Revenue beat(12)3.67%
Revenue beat(16)14
Avg Revenue beat(16)3.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-82.22%
EPS NY rev (1m)0%
EPS NY rev (3m)147.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.29 | ||
| P/FCF | 194.28 | ||
| P/OCF | 17.45 | ||
| P/B | 0.58 | ||
| P/tB | 0.58 | ||
| EV/EBITDA | -15.22 |
EPS(TTM)0
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.06
FCFY0.51%
OCF(TTM)0.65
OCFY5.73%
SpS39.1
BVpS19.54
TBVpS19.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.09% | ||
| ROE | 0.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 0.06% | ||
| GM | 72.44% | ||
| FCFM | 0.15% |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)57.45%
ROCE(5y)70.54%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 46.9% | ||
| Cap/Sales | 1.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 89.73% | ||
| Profit Quality | 260.48% | ||
| Current Ratio | 4.45 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 4.58 |
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)86.65%
Cap/Depr(5y)168.74%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.15%
Profit Quality(3y)359.98%
Profit Quality(5y)250.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-160%
EPS Next Y-78.11%
EPS Next 2Y-43.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-36.29%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-36.21%
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-120.14%
EBIT growth 3Y-55.18%
EBIT growth 5Y-26.54%
EBIT Next Year-105.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-99.63%
FCF growth 3Y-34.4%
FCF growth 5Y-25.51%
OCF growth 1Y-96.19%
OCF growth 3Y-36.26%
OCF growth 5Y-21.91%
MEDIFAST INC / MED FAQ
What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MED.
Can you provide the valuation status for MEDIFAST INC?
ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.
Can you provide the profitability details for MEDIFAST INC?
MEDIFAST INC (MED) has a profitability rating of 3 / 10.
Can you provide the financial health for MED stock?
The financial health rating of MEDIFAST INC (MED) is 9 / 10.